Patient-reported Anxiety: A Possible Predictor of Pediatric Inflammatory Bowel Disease Health Care Use.

Abstract:

BACKGROUND:Anxiety is linked with adverse health-related outcomes and increased health-seeking behaviors among patients with chronic illness. Yet, this relationship has received little attention in pediatric inflammatory bowel disease. The aim of this study was to examine whether anxiety symptoms predicted youth at increased risk for repeated disease relapse and greater gastrointestinal health care use over the subsequent 12 months. METHODS:Eighty-six pediatric patients aged 11 to 18 years (M = 14.7, SD = 2.0), and their caregivers completed a validated anxiety questionnaire during a gastrointestinal specialty appointment (baseline). Medical records were reviewed for the subsequent year to record the number of disease relapses and gastrointestinal health care services and generate disease activity scores at baseline and 12 months. Analysis of variance was used to examine anxiety levels between those who experienced ≤1 versus ≥2 disease relapses. Poisson regressions were used to model the relationship between child- and caregiver-reported anxiety and health care use, controlling for disease activity. RESULTS:The sample was predominantly white (81%) and male (56%). Patients with higher anxiety at baseline (M = 19.6; SD = 13.7) had more frequent (≥2) disease relapses compared with those with lower anxiety at baseline (M = 12.6; SD = 10.3). Higher anxiety, irrespective of reporter, also predicted greater total gastrointestinal health care use (P < 0.01). This included hospital-based interventions (P < 0.01), but not office encounters or outpatient endoscopic procedures. Findings remained significant after controlling for disease severity (P < 0.05). CONCLUSIONS:Assessment of anxiety may be one mechanism by which to identify those youth who are most vulnerable for disease exacerbation and costly interventions in the near future.

journal_name

Inflamm Bowel Dis

authors

Reigada LC,Satpute A,Hoogendoorn CJ,Cohen BH,Lai J,Bao R,Dubinsky MC,Benkov KJ

doi

10.1097/MIB.0000000000000864

subject

Has Abstract

pub_date

2016-09-01 00:00:00

pages

2127-33

issue

9

eissn

1078-0998

issn

1536-4844

journal_volume

22

pub_type

杂志文章
  • Short pediatric Crohn's disease activity index for quality improvement and observational research.

    abstract:BACKGROUND:Practical and objective instruments to assess pediatric Crohn's disease (CD) activity are required for observational research and quality improvement. The objectives were: 1) to determine the feasibility of completing the Pediatric Crohn's Disease Activity Index (PCDAI) and the Abbreviated PCDAI (APCDAI); an...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21452

    authors: Kappelman MD,Crandall WV,Colletti RB,Goudie A,Leibowitz IH,Duffy L,Milov DE,Kim SC,Schoen BT,Patel AS,Grunow J,Larry E,Fairbrother G,Margolis P

    更新日期:2011-01-01 00:00:00

  • Use of Social Media for Health-Related Tasks by Adolescents With Inflammatory Bowel Disease: A Step in the Pathway of Transition.

    abstract:Background:Social media is commonly used among the adolescent and young adult population, including those with chronic diseases. For adults, these platforms have been shown to be a major source of health information. Our aims were to explore how youth with inflammatory bowel disease (IBD) use social media for (1) disea...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy021

    authors: Szeto W,van der Bent A,Petty CR,Reich J,Farraye F,Fishman LN

    更新日期:2018-05-18 00:00:00

  • Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.

    abstract::: Primary nonresponse and primary nonremission are important limitations of tumor necrosis factor (TNF) antagonists, occurring in 10% to 40% and 50% to 80% of patients with inflammatory bowel disease, respectively. The magnitude of primary nonresponse differs between phase III clinical trials and cohort studies, indic...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000202

    authors: Papamichael K,Gils A,Rutgeerts P,Levesque BG,Vermeire S,Sandborn WJ,Vande Casteele N

    更新日期:2015-01-01 00:00:00

  • Effects of T cell-induced colonic inflammation on epithelial barrier function.

    abstract:BACKGROUND:Epithelial barrier disturbance is thought to contribute to the pathogenesis of inflammatory bowel diseases; however, it remains unclear whether it is a primary defect participating to the onset of inflammation or only a consequence of sustained inflammation. METHODS:A time course study of epithelial barrier...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21211

    authors: Suenaert P,Maerten P,Van Assche G,Van Driessche W,Geboes K,Bulteel V,Simaels J,Augustijns P,Ceuppens JL,Rutgeerts P,Perrier C

    更新日期:2010-08-01 00:00:00

  • Dipeptidyl peptidase expression during experimental colitis in mice.

    abstract:BACKGROUND:We have previously demonstrated that inhibition of dipeptidyl peptidase (DP) activity partially attenuates dextran sulfate sodium (DSS) colitis in mice. The aim of this study was to further investigate the mechanisms of this protection. MATERIALS AND METHODS:Wildtype (WT) and DPIV(-/-) mice consumed 2% DSS ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21241

    authors: Yazbeck R,Sulda ML,Howarth GS,Bleich A,Raber K,von Hörsten S,Holst JJ,Abbott CA

    更新日期:2010-08-01 00:00:00

  • Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse.

    abstract:BACKGROUND:We assessed whether selective granulocyte and monocyte/macrophage adsorption apheresis maintained clinical remission in asymptomatic inflammatory bowel disease (IBD) patients at significant risk of clinical relapse. METHODS:Sixty asymptomatic patients (age 18-70 years) with IBD (in clinical remission) with ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/ibd.20505

    authors: Maiden L,Takeuchi K,Baur R,Bjarnason I,O'Donohue J,Forgacs I,Chung-Faye G,Sanderson J,Bjarnason I

    更新日期:2008-10-01 00:00:00

  • When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations.

    abstract:BACKGROUND:If dysplasia is found on biopsies during surveillance colonoscopy for ulcerative colitis (UC), many experts recommend colectomy given the substantial risk of synchronous colon cancer. The objective was to learn if UC patients' perceptions of their colon cancer risk and if their preferences for elective colec...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1002/ibd.21233

    authors: Siegel CA,Schwartz LM,Woloshin S,Cole EB,Rubin DT,Vay T,Baars J,Sands BE

    更新日期:2010-10-01 00:00:00

  • Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome.

    abstract:BACKGROUND:Glycobiology is an underexplored research area in inflammatory bowel disease (IBD), and glycans are relevant to many etiological mechanisms described in IBD. Alterations in N-glycans attached to the immunoglobulin G (IgG) Fc fragment can affect molecular structure and immunological function. Recent genome-wi...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000372

    authors: Trbojević Akmačić I,Ventham NT,Theodoratou E,Vučković F,Kennedy NA,Krištić J,Nimmo ER,Kalla R,Drummond H,Štambuk J,Dunlop MG,Novokmet M,Aulchenko Y,Gornik O,Campbell H,Pučić Baković M,Satsangi J,Lauc G,IBD-BIOM Consor

    更新日期:2015-06-01 00:00:00

  • Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.

    abstract:BACKGROUND:The purpose of the study was to determine the role of fecal calprotectin and lactoferrin in the prediction of inflammatory bowel disease relapses, both in patients with ulcerative colitis (UC) and Crohn's disease (CD), in a large, long-term, follow-up study. METHODS:The prospective multicenter study include...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1002/ibd.20933

    authors: Gisbert JP,Bermejo F,Pérez-Calle JL,Taxonera C,Vera I,McNicholl AG,Algaba A,López P,López-Palacios N,Calvo M,González-Lama Y,Carneros JA,Velasco M,Maté J

    更新日期:2009-08-01 00:00:00

  • Thromboembolism in pediatric inflammatory bowel disease: systematic review.

    abstract:BACKGROUND:Several studies suggest an increased risk of venous and arterial thromboembolism (TE) in adults with inflammatory bowel disease (IBD) compared to the general population. We performed a systematic review of studies on incidence and characteristic of TE in children with IBD. METHODS:We searched Medline, LILAC...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.21563

    authors: Lazzerini M,Bramuzzo M,Maschio M,Martelossi S,Ventura A

    更新日期:2011-10-01 00:00:00

  • Objective structured clinical examination as a novel tool in inflammatory bowel disease fellowship education.

    abstract:BACKGROUND:Experiential learning in medical education, as exemplified by objective structured clinical examinations (OSCEs), is a well-validated approach for improving trainee performance. Furthermore, the Accreditation Council for Graduate Medical Education has identified OSCEs as an ideal method for assessing the cor...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000317

    authors: Wolff MJ,Balzora S,Poles M,Zabar S,Mintah A,Wong L,Weinshel E,Malter LB

    更新日期:2015-04-01 00:00:00

  • Capsule Endoscopy, Magnetic Resonance Enterography, and Small Bowel Ultrasound for Evaluation of Postoperative Recurrence in Crohn's Disease: Systematic Review and Meta-Analysis.

    abstract:Background:Anastomotic recurrence is frequent in patients with Crohn's disease (CD) following ileocecal resection. The degree of endoscopic recurrence, quantified by the Rutgeerts score (RS), is correlated with the risk of clinical and surgical recurrence. Noninvasive modalities such as capsule endoscopy (CE), magnetic...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,meta分析

    doi:10.1093/ibd/izx027

    authors: Yung DE,Har-Noy O,Tham YS,Ben-Horin S,Eliakim R,Koulaouzidis A,Kopylov U

    更新日期:2017-12-19 00:00:00

  • Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohn's disease.

    abstract:BACKGROUND:Infliximab is efficacious in the management of moderate to severe Crohn's disease (CD). There are limited data regarding performance of infliximab in patients who require reinitiation of maintenance dosing following previous irregular exposure. METHODS:This was a retrospective, observational study of CD pat...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21164

    authors: Stein DJ,Ananthakrishnan AN,Issa M,Williams JB,Beaulieu DB,Zadvornova Y,Ward A,Johnson K,Knox JF,Skaros S,Binion DG

    更新日期:2010-07-01 00:00:00

  • MDR1 polymorphisms and response to azathioprine therapy in patients with Crohn's disease.

    abstract:BACKGROUND:To investigate the contribution of multidrug resistance 1 (MDR1) gene pharmacogenetics (G2677T/A and C3435T) to the efficacy of azathioprine in inducing remission in patients with Crohn's disease (CD). METHODS:A cohort of 327 unrelated Spanish patients with CD recruited from a single center was studied. All...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20044

    authors: Mendoza JL,Urcelay E,Lana R,Martín MC,López N,Guijarro LG,Mayol JA,Taxonera C,de la Concha EG,Peña AS,Díaz-Rubio M

    更新日期:2007-05-01 00:00:00

  • Targeted inhibition of heat shock protein 90 suppresses tumor necrosis factor-α and ameliorates murine intestinal inflammation.

    abstract::Inflammatory bowel diseases are chronic intestinal inflammatory diseases thought to reflect a dysregulated immune response. Although antibody-based inhibition of tumor necrosis factor-α (TNF-α) has provided relief to many inflammatory bowel diseases patients, these therapies are either ineffective in a patient subset ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.MIB.0000442839.28664.75

    authors: Collins CB,Strassheim D,Aherne CM,Yeckes AR,Jedlicka P,de Zoeten EF

    更新日期:2014-04-01 00:00:00

  • Connecting Families: A Pediatric IBD Center's Development and Implementation of a Volunteer Parent Mentor Program.

    abstract::It is estimated that over one million people are living with inflammatory bowel disease (IBD) in the United States and that 20-25% of those are children. Pediatric IBD presents with more severe and extensive disease when compared to adults. As with all pediatric chronic illnesses, the patient as well as their parents ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000733

    authors: Donegan A,Boyle B,Crandall W,Dotson JL,Lemont C,Moon T,Kim SC

    更新日期:2016-05-01 00:00:00

  • The INSPIRE study: are different personality traits related to disease-specific quality of life (IBDQ) in distressed patients with ulcerative colitis and Crohn's disease?

    abstract:BACKGROUND:To explore the relationship between personality and disease-specific quality of life [Inflammatory Bowel Disease Questionnaire (IBDQ)] in distressed [Perceived Stress Questionnaire (PSQ)] patients with ulcerative colitis (UC) and Crohn's disease (CD). METHODS:Included in the study were 56 patients with UC a...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1002/ibd.20367

    authors: Boye B,Jahnsen J,Mokleby K,Leganger S,Jantschek G,Jantschek I,Kunzendorf S,Benninghoven D,Wilhelmsen I,Sharpe M,Blomhoff S,Malt UF,Lundin KE

    更新日期:2008-05-01 00:00:00

  • Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease.

    abstract:BACKGROUND:The goal of this study was to determine the rate of work disability, unemployment, and sick leave in an unselected inflammatory bowel disease (IBD) cohort and to measure the effect of working status and disability on the patient's health-related quality of life (HRQOL). MATERIALS AND METHODS:All eligible pa...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.MIB.0000218762.61217.4a

    authors: Bernklev T,Jahnsen J,Henriksen M,Lygren I,Aadland E,Sauar J,Schulz T,Stray N,Vatn M,Moum B

    更新日期:2006-05-01 00:00:00

  • Negative feedback regulation of colitogenic CD4+ T cells by increased granulopoiesis.

    abstract:BACKGROUND:Chronic inflammatory diseases are characterized by massive infiltration of innate and acquired immune cells in inflammatory sites. However, it remains unclear how these cells cooperate in the development of disease. Although bone marrow (BM) is a primary site for hematopoiesis of immune cells except T cells,...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20531

    authors: Nemoto Y,Kanai T,Tohda S,Totsuka T,Okamoto R,Tsuchiya K,Nakamura T,Sakamoto N,Fukuda T,Miura O,Yagita H,Watanabe M

    更新日期:2008-11-01 00:00:00

  • Loss of phosphoinositide 3-kinase P110γ is protective in the acute phase but detrimental in the resolution phase of hapten-induced colitis.

    abstract:BACKGROUND:Pharmacologic inhibition or genetic ablation of phosphoinositide 3-kinase gamma (PI3Kγ) has been shown to be protective against experimental colitis. However, the role of PI3Kγ in the resolution phase of colitis remains unexplored. In this study, we assess the effects of genetic knockout of PI3Kγ on the indu...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0b013e31827feb84

    authors: Prescott D,Atkinson B,Döring A,Brown S,Petri B,McKay DM,Waterhouse CC

    更新日期:2013-03-01 00:00:00

  • Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis.

    abstract:BACKGROUND:Previous systematic cumulative analyses of the placebo arm in ulcerative colitis (UC) were limited by the wide heterogeneity in the scores and definitions of response. We aimed at estimating the placebo rates of remission, response, and mucosal healing (MH) in phase 2 and 3 randomized placebo-controlled tria...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,meta分析

    doi:10.1093/ibd/izy365

    authors: Macaluso FS,Maida M,Ventimiglia M,Renna S,Cottone M,Orlando A

    更新日期:2019-05-04 00:00:00

  • The case for using 5-aminosalicyclates in Crohn's disease: pro.

    abstract::Mesalamine has a well-established role in the management of ulcerative colitis. However, its role in the management of Crohn's disease (CD) is less clear. Studies evaluating its therapeutic value in CD have produced both positive and negative results. Meta-analyses have not clarified the situation, possibly because th...

    journal_title:Inflammatory bowel diseases

    pub_type: 评论,社论

    doi:10.1097/01.mib.0000160743.24772.69

    authors: Hanauer SB

    更新日期:2005-06-01 00:00:00

  • How to Optimize Colon Cancer Surveillance in Inflammatory Bowel Disease Patients.

    abstract::Colitis-associated colorectal neoplasia (CRN) is a well-known complication of chronic inflammation of the colon either with ulcerative colitis (UC) or colonic Crohn's disease (CD). Studies have shown that inflammatory bowel disease (IBD) patients have an overall higher risk for colorectal dysplasia and cancer compared...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0000000000000685

    authors: Gaidos JK,Bickston SJ

    更新日期:2016-05-01 00:00:00

  • Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study.

    abstract:BACKGROUND:Vedolizumab is a gut-selective biologic that has shown efficacy in ulcerative colitis (UC) and Crohn's disease (CD). We studied the pharmacokinetics, pharmacodynamics, safety, tolerability, and efficacy of a new formulation of vedolizumab produced by an improved manufacturing process. METHODS:UC patients we...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/ibd.21896

    authors: Parikh A,Leach T,Wyant T,Scholz C,Sankoh S,Mould DR,Ponich T,Fox I,Feagan BG

    更新日期:2012-08-01 00:00:00

  • CCL2 (pM levels) as a therapeutic agent in Inflammatory Bowel Disease models in mice.

    abstract:BACKGROUND:Chemokines regulate the pathways that restrict homing of specific subsets of immune cells, and thereby fine tune the immune response at specific lymphoid and peripheral tissues. CCL2 is a chemokine that induces migration of monocytes, memory T cells, and dendritic cells. Previously, we demonstrated that pM l...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21254

    authors: Maharshak N,Hart G,Ron E,Zelman E,Sagiv A,Arber N,Brazowski E,Margalit R,Elinav E,Shachar I

    更新日期:2010-09-01 00:00:00

  • Eosinophils and IL-33 Perpetuate Chronic Inflammation and Fibrosis in a Pediatric Population with Stricturing Crohn's Ileitis.

    abstract:BACKGROUND:Fibrostenosis and stricture are well-recognized endpoints in Crohn's disease (CD). We hypothesized that stricturing CD is characterized by eosinophilia and epithelial IL-33. We proposed that eosinophil exposure to IL-33 would perpetuate inflammatory chronicity and subsequent fibrostenosis. METHODS:We perfor...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000512

    authors: Masterson JC,Capocelli KE,Hosford L,Biette K,McNamee EN,de Zoeten EF,Harris R,Fernando SD,Jedlicka P,Protheroe C,Lee JJ,Furuta GT

    更新日期:2015-10-01 00:00:00

  • Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model.

    abstract:Background:Vedolizumab, an α4β7 integrin monoclonal antibody inhibiting gut lymphocyte trafficking, is an effective treatment for ulcerative colitis (UC). We evaluated the optimal position of vedolizumab in the UC treatment paradigm. Methods:Using Markov modeling, we assessed multiple algorithms for the treatment of U...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izx045

    authors: Scott FI,Shah Y,Lasch K,Luo M,Lewis JD

    更新日期:2018-01-18 00:00:00

  • miR-29a-5p/STAT3 Positive Feedback Loop Regulates TETs in Colitis-Associated Colorectal Cancer.

    abstract:BACKGROUND:Interleukin (IL)-6/signal transducers and activators of transcription 3 (STAT3) signaling plays an important role in the development of colitis-associated colorectal cancer (CAC). The mechanism of CAC formation remains unclear, and the relationship between miRNAs and the IL-6/STAT3 signaling pathway in the d...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz281

    authors: Wang A,Deng S,Chen X,Yu C,Du Q,Wu Y,Chen G,Hu L,Hu C,Li Y

    更新日期:2020-03-04 00:00:00

  • Pediatric Inflammatory Bowel Diseases: Should We Be Looking for Kidney Abnormalities?

    abstract:Background:Kidney disease has been reported in adults with inflammatory bowel disease (IBD) and is regarded an extraintestinal manifestation or more rarely a side effect of the medical treatment. Methods:In this cross-sectional study we describe the extent of kidney pathology in a cohort of 56 children with IBD. Blood...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy166

    authors: Lauritzen D,Andreassen BU,Heegaard NHH,Klinge LG,Walsted AM,Neland M,Nielsen RG,Wittenhagen P

    更新日期:2018-11-29 00:00:00

  • VSL#3 Probiotic Stimulates T-cell Protein Tyrosine Phosphatase-mediated Recovery of IFN-γ-induced Intestinal Epithelial Barrier Defects.

    abstract:BACKGROUND:VSL#3 is a probiotic compound that has been used in the treatment of inflammatory bowel disease. T-cell protein tyrosine phosphatase (TCPTP) is the protein product of the inflammatory bowel disease candidate gene, PTPN2, and we have previously shown that it protects epithelial barrier function. The aim of th...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000954

    authors: Krishnan M,Penrose HM,Shah NN,Marchelletta RR,McCole DF

    更新日期:2016-12-01 00:00:00